



Antibody Therapy for Hematologic Malignancies

Guest Editor:

Dr. Jonathan P. Butchar

The Ohio State University College
of Medicine, Columbus, OH, USA

Deadline for manuscript
submissions:

20 September 2024

Message from the Guest Editor

Dear Colleagues,

After the approval of rituximab for CLL in 1997, therapeutic antibodies have taken a major role in the treatment of this disease. Although highly effective Bruton tyrosine kinase inhibitors such as ibrutinib and acalabrutinib are now in common use, there continues to be a need for improved therapies due to resistance and relapse. Antibody therapy can be a key component of such improvements, as there is perpetual progress with the engineering and development of these agents. More effective antibodies, bi- and tri-specific designs and even cell-based antibody production strategies have emerged over the years. Combination treatments are likewise evolving, with obinutuzumab being used and tested with inhibitors of Bruton tyrosine kinase or other target proteins. Here, in this Special Issue, we wish to include manuscripts that focus on the mechanisms of antibody therapy for CLL, on cutting-edge developments and on what the future may hold. Collectively, we can showcase this established yet still-developing field that continues to impact CLL treatment.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Maurizio Battino

Department of
Odontostomatologic and
Specialized Clinical Sciences,
Sez-Biochimica, Faculty of
Medicine, Università Politecnica
delle Marche, Via Ranieri 65,
60100 Ancona, Italy

Message from the Editor-in-Chief

The International Journal of Molecular Sciences (*IJMS*, ISSN 1422-0067) is an open access journal, which was established in 2000. The journal aims to provide a forum for scholarly research on a range of topics, including biochemistry, molecular and cell biology, molecular biophysics, molecular medicine, and all aspects of molecular research in chemistry. *IJMS* publishes both original research and review articles, and regularly publishes special issues to highlight advances at the cutting edge of research. We invite you to read recent articles published in *IJMS* and consider publishing your next paper with us.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, MEDLINE, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (*Biochemistry & Molecular Biology*) / CiteScore - Q1 (*Inorganic Chemistry*)

Contact Us

*International Journal of Molecular
Sciences* Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/ijms
ijms@mdpi.com
X@IJMS_MDPI